Wednesday, April 30, 2008
The Texas Therapeutics Institute Program
| 8:00 am | Introduction of attendees and Concept of the Texas Therapeutics Institute C. Thomas Caskey, MD, FACP Director & CEO The Brown Foundation Institute of Molecular Medicine (IMM) |
| Presentation of The Texas Therapeutics Institute Program | |
| 8:30 am | C. Thomas Caskey, MD, FACP |
| 8:40 am | Jonathan Sessler, Ph.D. |
| 8:50 am | Garth Powis, D.Phil. |
| 9:00 am | Intellectual Property Issues Bruce Butler, Ph.D. University of Texas Medical School at Houston |
| 9:30 am | UK Program Presentation; Approach to technology development and commercialization Dominique Kleyn BSc MBA DIC Head of BioPharma Business Development and Cathy J. Tralau-Stewart, PhD Head Drug Discovery Program, Imperial College London |
| 10:30 am | Translational medicine in drug discovery and early development Prof. Lefkos Middleton Professor of Clinical Neurology and Head, Division of Neuroscience and Mental Health, Imperial College (UK) |
| 10:50 am | Drug Induced hypothermia |
| 11:10 am | Recombinant fusion constructs for cancer therapy development of a robust, commercial-Type pipeline in an academic setting Mike Rosenblum, Ph.D MD Anderson |
| 11:30 am | Strategies to identify novel targets for therapeutic intervention in chronic inflammatory disease Professor Fionula M Brennan Professor of Cytokine Immunopathology (Tenure) Director of Postgraduate Studies Honorary Senior Research Fellow/Group Leader Cytokine Biology Kennedy Institute of Rheumatology, Faculty of Medicine Imperial College, London, UK |
| 1:00 pm | Translating Novel cancer targets towards clinical validation at Imperial College Prof. Charles Coombes Head, Department of Oncology, Director of Cancer Research (UK) Laboratories Imperial College London |
| 1:20 pm | Inhibiting the hypoxia response for cancer therapy Garth Powis, D.Phil. MD Anderson |
| 1:40 pm | Anti-cancer molecules developed at UT that have undergone clinical trials Jonathan Sessler, Ph.D. Roland Pettit Centennial Professor Department of Chemistry and Biochemistry – UT Austin |
| 2:00 pm | Salivary diagnostics as it relates to ductal breast cancer Charles Streckfus, DDS, MA Professor – UT Dental Branch |
| 2:20 pm | Novel nanoparticle contrast agents for next generation imagining-based diagnostics Ananth Annapragada, Ph.D. Associate Professor of Health Information Sciences - University of Texas |
| 2:40 pm | Passive protection from enterococcal infection Barrett Harvey, Ph.D. Assistant Professor – UT-IMM |
| 3:30 pm | Engineered antibody as a cure/prophylactic for anthrax Brent Iverson, Ph.D. Professor Department of Chemistry and Biochemistry – UT Austin |
| 3:50 pm | Texas Emerging Technology Fund Mark M. Ellison Director Texas Emerging Technology Fund Office of the Governor |
| 4:10 pm | Building Partnerships Daniel Getman, Ph.D. VP - Pfizer Global Research & Development. |
| 4:20 pm | Jim Shaeffer, Ph.D. Executive Director - Licensing and External Research-West Coast Merck Research and Laboratories |
| 4:30 pm | Kerry Blanchard, M.D., Ph.D. Executive Director and COO Discovery Research and Clinical Investigation – Lilly |
| 4:40 pm | Ruhi Khan, MBA Senior Director, Business Development Lexicon |
| 5:00 pm | Brian Bates, Ph.D. Wyeth Research |
| 5:10 pm | David E. Smith, Ph.D. Associate Director, Scientific Awareness Luminex Corporation |